Literature DB >> 31558666

IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma.

Santiago Barrio1, Umair Munawar2, Yuan Xiao Zhu3, Nicola Giesen4, Chang-Xin Shi3, Matteo Da Viá1, Ricardo Sanchez5, Laura Bruins3, Theresa Demler2, Nicole Müller1, Larissa Haertle1, Andoni Garitano1, Torsten Steinbrunn1, Sophia Danhof1, Isabel Cuenca5, Clara Barrio-Garcia6, Esteban Braggio3, Andreas Rosenwald7, Joaquin Martinez-Lopez5, Leo Rasche1, Marc S Raab4, A Keith Stewart3,8, Hermann Einsele1, Thorsten Stühmer2, K Martin Kortüm9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31558666      PMCID： PMC7193510          DOI： 10.3324/haematol.2019.217943

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  The molecular basis of CRL4DDB2/CSA ubiquitin ligase architecture, targeting, and activation.

Authors:  Eric S Fischer; Andrea Scrima; Kerstin Böhm; Syota Matsumoto; Gondichatnahalli M Lingaraju; Mahamadou Faty; Takeshi Yasuda; Simone Cavadini; Mitsuo Wakasugi; Fumio Hanaoka; Shigenori Iwai; Heinz Gut; Kaoru Sugasawa; Nicolas H Thomä
Journal:  Cell       Date:  2011-11-23       Impact factor: 41.582

Review 2.  Cereblon binding molecules in multiple myeloma.

Authors:  K M Kortüm; Y X Zhu; C X Shi; P Jedlowski; A K Stewart
Journal:  Blood Rev       Date:  2015-03-27       Impact factor: 8.250

3.  Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.

Authors:  Yuan Xiao Zhu; Esteban Braggio; Chang-Xin Shi; K Martin Kortuem; Laura A Bruins; Jessica E Schmidt; Xiu-Bao Chang; Paul Langlais; Moulun Luo; Patrick Jedlowski; Betsy LaPlant; Kristina Laumann; Rafael Fonseca; P Leif Bergsagel; Joseph Mikhael; Martha Lacy; Mia D Champion; A Keith Stewart
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

4.  Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.

Authors:  Jan Krönke; Namrata D Udeshi; Anupama Narla; Peter Grauman; Slater N Hurst; Marie McConkey; Tanya Svinkina; Dirk Heckl; Eamon Comer; Xiaoyu Li; Christie Ciarlo; Emily Hartman; Nikhil Munshi; Monica Schenone; Stuart L Schreiber; Steven A Carr; Benjamin L Ebert
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

5.  Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.

Authors:  Philip P Chamberlain; Antonia Lopez-Girona; Karen Miller; Gilles Carmel; Barbra Pagarigan; Barbara Chie-Leon; Emily Rychak; Laura G Corral; Yan J Ren; Maria Wang; Mariko Riley; Silvia L Delker; Takumi Ito; Hideki Ando; Tomoyuki Mori; Yoshinori Hirano; Hiroshi Handa; Toshio Hakoshima; Thomas O Daniel; Brian E Cathers
Journal:  Nat Struct Mol Biol       Date:  2014-08-10       Impact factor: 15.369

6.  Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.

Authors:  Klaus M Kortüm; Christian Langer; Jorge Monge; Laura Bruins; Jan B Egan; Yuan X Zhu; Chang Xin Shi; Patrick Jedlowski; Jessica Schmidt; Juhi Ojha; Lars Bullinger; Peter Liebisch; Miriam Kull; Mia D Champion; Scott Van Wier; Gregory Ahmann; Leo Rasche; Stefan Knop; Rafael Fonseca; Hermann Einsele; A Keith Stewart; Esteban Braggio
Journal:  Br J Haematol       Date:  2014-10-10       Impact factor: 6.998

7.  SDM: a server for predicting effects of mutations on protein stability.

Authors:  Arun Prasad Pandurangan; Bernardo Ochoa-Montaño; David B Ascher; Tom L Blundell
Journal:  Nucleic Acids Res       Date:  2017-07-03       Impact factor: 16.971

8.  Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.

Authors:  K M Kortuem; E Braggio; L Bruins; S Barrio; C S Shi; Y X Zhu; R Tibes; D Viswanatha; P Votruba; G Ahmann; R Fonseca; P Jedlowski; I Schlam; S Kumar; P L Bergsagel; A K Stewart
Journal:  Blood Cancer J       Date:  2016-02-26       Impact factor: 11.037

9.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.

Authors:  Jens G Lohr; Petar Stojanov; Scott L Carter; Peter Cruz-Gordillo; Michael S Lawrence; Daniel Auclair; Carrie Sougnez; Birgit Knoechel; Joshua Gould; Gordon Saksena; Kristian Cibulskis; Aaron McKenna; Michael A Chapman; Ravid Straussman; Joan Levy; Louise M Perkins; Jonathan J Keats; Steven E Schumacher; Mara Rosenberg; Gad Getz; Todd R Golub
Journal:  Cancer Cell       Date:  2014-01-13       Impact factor: 31.743

10.  Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

Authors:  Niccolo Bolli; Hervé Avet-Loiseau; David C Wedge; Peter Van Loo; Ludmil B Alexandrov; Inigo Martincorena; Kevin J Dawson; Francesco Iorio; Serena Nik-Zainal; Graham R Bignell; Jonathan W Hinton; Yilong Li; Jose M C Tubio; Stuart McLaren; Sarah O' Meara; Adam P Butler; Jon W Teague; Laura Mudie; Elizabeth Anderson; Naim Rashid; Yu-Tzu Tai; Masood A Shammas; Adam S Sperling; Mariateresa Fulciniti; Paul G Richardson; Giovanni Parmigiani; Florence Magrangeas; Stephane Minvielle; Philippe Moreau; Michel Attal; Thierry Facon; P Andrew Futreal; Kenneth C Anderson; Peter J Campbell; Nikhil C Munshi
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919
View more
  14 in total

1.  IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target.

Authors:  Chih-Yi Lin; Chung-Jen Yu; Chia-I Shen; Chun-Yu Liu; Ta-Chung Chao; Chi-Cheng Huang; Ling-Ming Tseng; Jiun-I Lai
Journal:  Med Oncol       Date:  2022-09-30       Impact factor: 3.738

Review 2.  The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma.

Authors:  Mark Sellin; Stephanie Berg; Patrick Hagen; Jiwang Zhang
Journal:  Transl Oncol       Date:  2022-06-01       Impact factor: 4.803

Review 3.  Overcoming Cancer Drug Resistance Utilizing PROTAC Technology.

Authors:  Matthew R Burke; Alexis R Smith; Guangrong Zheng
Journal:  Front Cell Dev Biol       Date:  2022-04-25

Review 4.  A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity.

Authors:  Matteo C Da Vià; Bachisio Ziccheddu; Akihiro Maeda; Filippo Bagnoli; Giulia Perrone; Niccolò Bolli
Journal:  Hemasphere       Date:  2020-11-24

5.  Targeting RFWD2 as an Effective Strategy to Inhibit Cellular Proliferation and Overcome Drug Resistance to Proteasome Inhibitor in Multiple Myeloma.

Authors:  Mengjie Guo; Pinggang Ding; Zhen Zhu; Lu Fan; Yanyan Zhou; Shu Yang; Ye Yang; Chunyan Gu
Journal:  Front Cell Dev Biol       Date:  2021-04-21

6.  Exploiting Interdata Relationships in Prostate Cancer Proteomes: Clinical Significance of HO-1 Interactors.

Authors:  Sofia Lage-Vickers; Pablo Sanchis; Juan Bizzotto; Ayelen Toro; Agustina Sabater; Rosario Lavignolle; Nicolas Anselmino; Estefania Labanca; Alejandra Paez; Nora Navone; Maria P Valacco; Javier Cotignola; Elba Vazquez; Geraldine Gueron
Journal:  Antioxidants (Basel)       Date:  2022-01-31

7.  Comprehensive characterization of the epigenetic landscape in Multiple Myeloma.

Authors:  Elina Alaterre; Sara Ovejero; Laurie Herviou; Hugues de Boussac; Giorgio Papadopoulos; Marta Kulis; Stéphanie Boireau; Nicolas Robert; Guilhem Requirand; Angélique Bruyer; Guillaume Cartron; Laure Vincent; Anne Marie Martinez; José Ignacio Martin-Subero; Giacomo Cavalli; Jerome Moreaux
Journal:  Theranostics       Date:  2022-01-16       Impact factor: 11.556

8.  Profiling the Landscape of Drug Resistance Mutations in Neosubstrates to Molecular Glue Degraders.

Authors:  Pallavi M Gosavi; Kevin C Ngan; Megan J R Yeo; Cindy Su; Jiaming Li; Nicholas Z Lue; Samuel M Hoenig; Brian B Liau
Journal:  ACS Cent Sci       Date:  2022-02-14       Impact factor: 18.728

9.  Cereblon enhancer methylation and IMiD resistance in multiple myeloma.

Authors:  Larissa Haertle; Santiago Barrio; Umair Munawar; Seungbin Han; Xiang Zhou; Cornelia Vogt; Rafael Alonso Fernández; Max Bittrich; Yanira Ruiz-Heredia; Matteo Da Viá; Josip Zovko; Andoni Garitano-Trojaola; Niccolò Bolli; Anna Ruckdeschel; Thorsten Stühmer; Manik Chatterjee; Miriam Kull; Jan Krönke; Xabier Agirre; Jose I Martin-Subero; Peter Raab; Hermann Einsele; Leo Rasche; Joaquin Martinez-Lopez; Thomas Haaf; K Martin Kortüm
Journal:  Blood       Date:  2021-11-04       Impact factor: 22.113

Review 10.  PROTAC targeted protein degraders: the past is prologue.

Authors:  Miklós Békés; David R Langley; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2022-01-18       Impact factor: 112.288
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.